Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Genomic prognostics in PC salvage radiation

Felix Feng • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Prostate Cancer Bicalutamide

Felix Feng, MD, University of California San Francisco, San Francisco, CA, discusses the validation of a prognostic genomic classifier for salvage radiotherapy prostate cancer (PC) patients from the RTOG 9601 trial who had PSA recurrences after prostatectomy. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Felix Feng

0:58
Biomarker highlights from ASCO GU
Felix Feng • 13 Feb 2020
1:14
Prostate cancer: biomarkers
Felix Feng • 13 Feb 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals